BRKR
Bruker Corp
$
34.540
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
34.630
Open
32.640
VWAP
34.03
Vol
2.48M
Mkt Cap
5.24B
Low
32.570
Amount
84.48M
EV/EBITDA(TTM)
13.45
Total Shares
151.34M
EV
7.32B
EV/OCF(TTM)
44.10
P/S(TTM)
1.43
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
805.48M
+0.51%
0.475
+1%
1.00B
+2.3%
0.873
+14.92%
849.33M
-1.74%
0.325
-45.89%
Estimates Revision
The market is revising Upward the revenue expectations for Bruker Corporation (BRKR) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by -10.84%.
Revenue Estimates for FY2025
Revise Upward
+0.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-1.47%
In Past 3 Month
Stock Price
Go Down
-10.84%
In Past 3 Month
11 Analyst Rating
34.48% Upside
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 46.45 USD with a low forecast of 38.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
5 Hold
0 Sell
Moderate Buy
34.48% Upside
Current: 34.540
Low
38.00
Averages
46.45
High
65.00
34.48% Upside
Current: 34.540
Low
38.00
Averages
46.45
High
65.00
Stifel
Daniel Arias
Hold
downgrade
$48 -> $40
2025-08-05
Reason
Stifel
Daniel Arias
Price Target
$48 -> $40
2025-08-05
downgrade
Hold
Reason
Stifel analyst Daniel Arias lowered the firm's price target on Bruker to $40 from $48 and keeps a Hold rating on the shares. The company's Q2 miss and revised outlook "featured a combination of both expected and unexpected factors," the analyst tells investors. The EPS guidance reset "should clear the deck on 2025 earnings," and "there will come a time again to own" the stock, but in the firm's view "we're not there yet," the analyst added.
Jefferies
Buy
downgrade
$70 -> $60
2025-08-04
Reason
Jefferies
Price Target
$70 -> $60
2025-08-04
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Bruker to $60 from $70 and keeps a Buy rating on the shares. Although B2B was better than feared, the magnitude of the core growth reset and EPS were disappointing, especially given the chance to reset the bar more meaningfully coming out of Q1, the firm notes. Cost-outs should help 2026 EPS, and valuation remains attractive. However, Jefferies believes patience will be required as Bruker needs to rebuild credibility and return to a cadence of meeting or beating numbers.
Barclays
Luke Sergott
Overweight
downgrade
$46 -> $43
2025-08-04
Reason
Barclays
Luke Sergott
Price Target
$46 -> $43
2025-08-04
downgrade
Overweight
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Bruker to $43 from $46 and keeps an Overweight rating on the shares. The firm said it knew Q2 orders were going to be soft, and the biggest question on the day was what guidance implied for the second half. With a steep second half ramp, and most coming in Q4, investors have little appetite for this type of outlook in the uncertain macro, and as such, Bruker sentiment is likely to remain bearish, the analyst tells investors in a research note.
Citi
Neutral
downgrade
$40 -> $38
2025-08-04
Reason
Citi
Price Target
$40 -> $38
2025-08-04
downgrade
Neutral
Reason
Citi lowered the firm's price target on Bruker to $38 from $40 and keeps a Neutral rating on the shares after the company reported Q2 results and lowered FY25 guidance, citing weaker than expected end markets, soft demand in China, and tariffs. The firm's estimates move lower following the guidance cut, the analyst noted.
BofA
Buy
downgrade
$61 -> $50
2025-06-26
Reason
BofA
Price Target
$61 -> $50
2025-06-26
downgrade
Buy
Reason
BofA lowered the firm's price target on Bruker to $50 from $61 and keeps a Buy rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.
Citi
Patrick Donnelly
Buy -> Neutral
downgrade
$50 -> $40
2025-05-22
Reason
Citi
Patrick Donnelly
Price Target
$50 -> $40
2025-05-22
downgrade
Buy -> Neutral
Reason
Citi analyst Patrick Donnelly downgraded Bruker to Neutral from Buy with a price target of $40, down from $50. The company's exposure to the U.S. academic and government market may lead to order volatility which may linger into 2026, the analyst tells investors in a research note. The firm says that even if the National Institutes of Health budget cut comes in lighter than expected, academic and research institutions will remain more cautious on spending. Citi is more cautious on forward years than the recent share price decline suggests.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bruker Corp (BRKR.O) is 14.34, compared to its 5-year average forward P/E of 27.31. For a more detailed relative valuation and DCF analysis to assess Bruker Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Undervalued
5Y Average PE
27.31
Current PE
14.34
Overvalued PE
33.52
Undervalued PE
21.10
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
17.95
Current EV/EBITDA
12.05
Overvalued EV/EBITDA
21.09
Undervalued EV/EBITDA
14.81
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
3.42
Current PS
1.34
Overvalued PS
4.31
Undervalued PS
2.54
Financials
Annual
Quarterly
FY2025Q2
YoY :
-0.41%
797.40M
Total Revenue
FY2025Q2
YoY :
-61.03%
28.80M
Operating Profit
FY2025Q2
YoY :
-53.85%
3.60M
Net Income after Tax
FY2025Q2
YoY :
0.00%
0.05
EPS - Diluted
FY2025Q2
YoY :
+533.19%
-148.80M
Free Cash Flow
FY2025Q2
YoY :
-6.58%
45.44
Gross Profit Margin - %
FY2025Q2
YoY :
-73.47%
1.43
FCF Margin - %
FY2025Q2
YoY :
-44.21%
0.53
Net Margin - %
FY2025Q2
YoY :
-75.57%
2.80
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
193.7K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
1
100.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
153.2K
Volume
1
6-9
Months
1.0M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
316.0K
Volume
Months
6-9
7
3.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
193.7K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
1
100.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BRKR News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
09:41:33
Bruker signs $27M in explosives, chemical trace detection solutions contracts
2025-08-04 (ET)
2025-08-04
11:03:34
Video: Why These Stocks Are Moving Today
2025-08-04
10:00:53
Bruker falls -15.2%
Sign Up For More Events
Sign Up For More Events
News
8.0
08-12NASDAQ.COMDaily Dividend Report: JJSF,NWL,TROW,DLR,BRKR
9.5
08-05BenzingaThese Analysts Slash Their Forecasts On Bruker After Weaker-Than-Expected Q2 Results
6.5
08-05BenzingaBruker Stock: Caution Warranted Despite Bullish Analyst Calls
Sign Up For More News
People Also Watch
ENPH
Enphase Energy Inc
34.220
USD
+1.97%
LW
Lamb Weston Holdings Inc
54.730
USD
+3.32%
DCI
Donaldson Company Inc
75.720
USD
+2.71%
OGE
OGE Energy Corp
45.650
USD
+1.06%
AOS
A O Smith Corp
73.640
USD
+3.24%
ZION
Zions Bancorporation NA
53.860
USD
+1.32%
AGNC
AGNC Investment Corp
9.660
USD
+2.11%
NYT
New York Times Co
60.620
USD
+4.50%
NBIS
Nebius Group NV
70.630
USD
-6.24%
MOS
Mosaic Co
32.210
USD
+3.27%
FAQ
What is Bruker Corp (BRKR) stock price today?
The current price of BRKR is 34.54 USD — it has increased 6.74 % in the last trading day.
What is Bruker Corp (BRKR)'s business?
What is the price predicton of BRKR Stock?
What is Bruker Corp (BRKR)'s revenue for the last quarter?
What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bruker Corp (BRKR)'s fundamentals?
How many employees does Bruker Corp (BRKR). have?